Jacob Chacko - 02 Jan 2026 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 16:40:09 UTC
Previous filing
17 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chacko Jacob PRESIDENT AND CEO, Director C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO /s/ Christian Kuhlen, attorney-in-fact 06 Jan 2026 0001608936

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Stock Option (right to buy) Award $0 +675,000 $0.000000 675,000 02 Jan 2026 Common Stock 675,000 $8.17 Direct F1
transaction ORIC Restricted Stock Unit Award $0 +112,500 $0.000000 112,500 02 Jan 2026 Common Stock 112,500 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
F3 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.